drugset / Trial / NCT07367555

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

NCT07367555

Phase 1 Completed 360 enrolled Ariba Shafiq
RandomizedParallel-groupSingle-blindTreatment

Summary

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Timeline

Start
2024-10-01
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 100 g Oral